Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Authors

Farrukh T Awan, Ran Liu, Hsin-Hui Huang, Matthew Bye, Kwang Woo Ahn, Gabriel Krigsfeld, Anat Raz, Heather Wolfe, Mehdi Hamadani

Published in

British journal of haematology. Aug 31, 2026. Epub Aug 31, 2026.

Abstract

After adjusting for confounders, the ibrutinib cohort had significantly better overall survival (adjusted hazard ratio, 0.39; 95% confidence interval, 0.23-0.68; p = 0.0008) than the allogeneic haematopoietic stem cell transplantation (alloHSCT) cohort. Our large, retrospective analysis suggests that ibrutinib treatment may offer improved overall survival and progression-free survival compared to alloHSCT in patients with relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma.

PMID:
42676008
Bibliographic data and abstract were imported from PubMed on 01 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.